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16RESEARCH Open AccessClinically significant bleeding in incurable cancer
patients: effectiveness of hemostatic radiotherapy
Nikola Cihoric1, Susanne Crowe2, Steffen Eychmüller3, Daniel M Aebersold1 and Pirus Ghadjar1*Abstract
Background: This study was performed to evaluate the outcome after hemostatic radiotherapy (RT) of significant
bleeding in incurable cancer patients.
Methods: Patients treated by hemostatic RT between November 2006 and February 2010 were retrospectively
analyzed. Bleeding was assessed according to the World Health Organization (WHO) scale (grade 0 = no bleeding,
1 = petechial bleeding, 2 = clinically significant bleeding, 3 = bleeding requiring transfusion, 4 = bleeding associated
with fatality). The primary endpoint was bleeding at the end of RT. Key secondary endpoints included overall
survival (OS) and acute toxicity. The bleeding score before and after RT were compared using the Wilcoxon signed
rank test. Time to event endpoints were estimated using the Kaplan Meier method.
Results: Overall 62 patients were analyzed including 1 patient whose benign cause of bleeding was
pseudomyxoma peritonei. Median age was 66 (range, 37–93) years. Before RT, bleeding was graded as 2 and 3 in
24 (39%) and 38 (61%) patients, respectively. A median dose of 20 (range, 5–45) Gy of hemostatic RT was applied to
the bleeding site. At the end of RT, there was a statistically significant difference in bleeding (p< 0.001); it was
graded as 0 (n= 39), 1 (n= 12), 2 (n= 6), 3 (n= 4) and 4 (n = 1). With a median follow-up of 19.3 (range, 0.3-19.3)
months, the 6-month OS rate was 43%. Forty patients died (65%); 5 due to bleeding. No grade 3 or above acute
toxicity was observed.
Conclusions: Hemostatic RT seems to be a safe and effective treatment for clinically and statistically significantly
reducing bleeding in incurable cancer patients.
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Bleeding in cancer patients can occur in a variety of
ways, from chronic occult bleeding to clinically signifi-
cant macroscopic bleeding or profound bleeding from
large blood vessels which may cause sudden death. It
can be the first symptom of a disease or develop later
along with disease progression. It has been estimated
that bleeding occurs in approximately 6-10% of patients
with advanced cancer; for at least some of these patients,
bleeding will be the direct cause of death [1].
Clinically significant bleeding commonly leads to
hospitalization. It is distressing to patients and their fam-
ilies; thus bleeding is likely to impact negatively upon
patient’s quality of life (QoL). The hemostatic effectiveness* Correspondence: pirus.ghadjar@insel.ch
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reproduction in any medium, provided the orof radiotherapy (RT) is usually visible after only a few frac-
tions of RT and generally explained by increased adhesion
of platelets to the vascular endothelium [2]. The long term
effect could be explained by causing vessel fibrosis com-
bined with tumor remission [3]. Although RT has been
used for decades as a non-invasive treatment for cancer
related bleeding, there is little published literature focusing
on hemostatic RT. The reduction of hemoptysis achieved
by palliative RT in non-small cell lung cancer (NSCLC)
has been demonstrated within prospective randomized
trials [4,5]. Moreover, several relatively small retrospective
studies have described the effectiveness of hemostatic RT
for vaginal bleeding caused by cervical or endometrial
cancer [6,7], bleeding from locally advanced bladder can-
cer [8], prostate cancer [9], rectal cancer [10] and gastric
cancer [11].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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after hemostatic RT in patients who suffered clinically
significant bleeding in different sites, primary tumors or
involved metastases.Methods
Patient selection
In this retrospective study all patients who were treated
by hemostatic RT, in the Department of Radiation On-
cology, Bern University Hospital, Switzerland between
November 2006 and February 2010, were selected. All of
these patients had advanced incurable cancer; 1 patient’s
benign cause of bleeding was pseudomyxoma peritonei.
Prior surgery, chemotherapy or RT was allowed as well
as prior hemostatic measures. Pretreatment investiga-
tions included complete medical history, physical exam-
ination and radiological or endoscopic examination to
confirm or diagnose the bleeding site, if needed. This
study was approved by the local ethics committee.
Treatment
Patients were either treated by external beam RT
(EBRT), high-dose rate brachytherapy (HDR-B) mono-
therapy or a combination of HDR-B and EBRT. EBRT
was applied using one of the following methods: a three-
dimensional conformal RT (3D-CRT), a conventional
two-dimensional RT or a volumetric modulated arc
technique. For 3D-CRT a dedicated computed tomog-
raphy (CT) scan was used for treatment planning. All
treatment plans were calculated by a dedicated treat-
ment planning system. EBRT was applied with photons
from a linear accelerator. RT could also be accompanied
by concomitant cisplatin based chemotherapy in certain
cases.
Due to the different fractionation schedules used the
dose prescriptions were translated into 3-Gy equivalent
doses (EQD3), assuming α/β= 10, according to the linear
quadratic model, with no correction for overall treat-
ment time, as a total dose of 30 Gy using daily fractions
of 3 Gy is a widely accepted and commonly used treat-
ment schedule for palliative RT.
Assessment and evaluations
Patients were initially seen daily by a radiation oncolo-
gist during RT, then twice weekly when the bleeding
completely stopped. Due to the limited life expectancy
of treated patients and their generally poor performance
status (PS), patients were commonly followed-up close
to their domicile either by their treating medical oncolo-
gist or family doctor. Therefore, in most cases, the
patients’ condition was continuously reported. These
reports together with documentation in case of further
treatment in Bern University Hospital and additionalinformation provided by the treating medical oncologist
or family doctor were used to assess bleeding status at
the end of follow-up and overall survival (OS).
The bleeding score was retrospectively assessed by one
single observer (NC) using all available clinical information.
Bleeding was assessed before RT, the end of RT and
the end of follow-up. It was graded according to the
World Health Organization (WHO) scale [12] (grade
0 = no bleeding, 1 = petechial bleeding, 2 = clinically sig-
nificant mild blood loss, 3 = gross blood loss requiring
transfusion, 4 = debilitating blood loss associated with
fatality).
OS was calculated from the last day of RT until death.
Patients not experiencing an event were censored at the
date of the last follow-up visit.
Toxicities were graded according to the National Can-
cer Institute Common Terminology Criteria for AEs
(CTCAE) version 3.0. Acute toxicity was defined as toxi-
cities occurring during or within three months after
completion of RT.
Statistical considerations
The primary endpoint was bleeding at the end of RT.
Secondary endpoints included bleeding at the end of fol-
low-up, OS as well as acute toxicity.
Bleeding before and after RT was compared using the
Wilcoxon signed rank test. OS was estimated using the
Kaplan Meier (KM) method. The median follow-up time
was calculated using the inverse KM method, the respect-
ive range is based on patients without an event. Categor-
ical variables were summarized using absolute and relative
frequencies; continuous variables by descriptive statistics.
To analyse potential associations between bleeding con-
trol and clinical variables, the following variables were
included: WHO bleeding score at the end of hemostatic
RT and at the end of follow-up (grade 0–1 vs. grade 2–4),
WHO bleeding score before hemostatic RT (grade 2 vs.
grade 3), age (≤ 66 years vs. > 66 years), sex, Karnowsky
PS (KPS) (≥ 50 vs. ≤ 40), histology (adenocarcinoma vs.
others), presence of liver metastasis (no vs. yes), bleeding
cause (primary tumor vs. metastasis), use of chemotherapy
before hemostatic RT (no vs. yes), other RT prior to
hemostatic RT (no vs. yes), time from first diagnosis to
hemostatic RT (≥12 months vs. < 12 months), use of any
other hemostatic measure (no vs. yes), dose of hemostatic
RT (< 30 Gy vs. ≥ 30 Gy), and compared using the
Chi-square test. Univariate and multivariate analyses for
OS were performed using Cox proportional hazards mod-
els and the backward selection method (criterion for re-
moval: p≥ 0.05). To be assessed in the multivariate
analysis, a variable first had to be significant (p ≤ 0.1) in
the univariate analysis. The data were analyzed in SPSS
(SPSS Inc., Chicago, IL, version 19.0) and SAS (Statistical
Analysis Systems Institute Inc, version 9.2).
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Patient characteristics
Between November 2006 and February 2010, 62 patients
were treated by hemostatic RT. Of these patients, 61 had
incurable cancer disease, either due to a locally advanced
primary tumor and/or presence of distant metastasis and
1 had pseudomyxoma peritonei. Median age was 66
(range, 37–93) years. Median time from the first diagno-
sis of the disease until start of hemostatic RT was 11
(range, 0.3-183) months. Before RT, median KPS was 40
(range, 20–80). Initial bleeding was graded as 2 and 3 in
24 (39%) and 38 (61%) patients, respectively. Six patients
were lost to follow-up and hence will only be included
in the evaluation of the primary endpoint. Further pa-
tient characteristics are summarized in Table 1.
Treatment
Prior to treatment, 8 patients (13%) had already under-
gone RT to the site which was currently bleeding as part
of their initial treatment, using a median dose of 61.5
(range, 10–70) Gy. Median time between primary RT
and hemostatic RT in these patients was 32 (range, 2–
128) months. Thirty-three patients (53%) received prior
chemotherapy; 8 (13%) of which received chemotherapy
within 1 month prior to hemostatic RT. Three patients
(5%) took anticoagulants, of whom 2 continued this
medication during and after hemostatic RT. Thirteen
patients (21%) had already undergone the following
hemostatic measures prior to hemostatic RT: vaginal
tamponade (n= 4), cauterization (n= 4), tumor resection
(n= 2), embolization (n= 2) and infiltration with adren-
aline (n= 1). However, these measures were not success-
ful, thus the patients were referred to RT. Hemostatic
RT was then given to the bleeding site. Further informa-
tion on treatment is summarized in Table 2.
Sixty patients (97%) were treated by EBRT alone using
either 3D-CRT (n = 58), conventional two-dimensional
RT (n = 1) or a volumetric modulated arc technique
(n = 1). The different fractionation schedules used are
summarized in Table 3. In 13 patients, the single dose
was adapted during RT for a variety of reasons. Median
single dose by EBRT for the remaining 47 patients was 3
(range, 2–8) Gy, 1 fraction prescribed per day, 5 days
per week. Of the remaining patients, 1 with esophageal
cancer was treated by HDR-B monotherapy (2 x 5 Gy)
and the other with cervical cancer was treated with
a combination of HDR-B (2 x 7 Gy) and 3D-CRT
(5 x 4 Gy).
Median total dose to the bleeding site by EBRT
(excluding the patient with HDR-B monotherapy) was
20 (range, 5–45) Gy. Median RT duration was 8.5
(range, 1–25) days. RT was accompanied by concomitant
cisplatin based chemotherapy in 2 patients (3%) with
NSCLC.Bleeding control at the end of RT
At the end of RT, the following bleeding grades were
observed in patients: 0 (n= 39), 1 (n= 12), 2 (n= 6), 3
(n= 4) and 4 (n= 1). It should be noted that 8 patients
with either grade 2 or 3 at the end of RT were treated
with less than 30 Gy. The incidence of bleeding was sta-
tistically significantly different from the bleeding status
prior to hemostatic RT (p < 0.001) (Figure 1).
Bleeding was improved in 54 patients (87%); 39 (63%)
of whom had a complete response (CR) to bleeding. Of
the remaining patients, bleeding was unchanged in 7
patients (11%) whilst 1 patient showed a progression in
bleeding (Figure 2). This elderly gastric cancer patient
died as a result of bleeding, after completion of 5 frac-
tions reaching a total dose of 9.4 Gy (first fraction
1.4 Gy due to technical problems, followed by 4 x 2 Gy).
The patient was originally referred to RT after repeated
non-successful cauterizations with grade 3 bleeding.
Using the Chi-square test, sex was found to be asso-
ciated with worse bleeding control at the end of
hemostatic RT (p= 0.0253). However, age, KPS, hist-
ology, presence of liver metastasis, use of chemotherapy
or other RT prior to hemostatic RT, time from first diag-
nosis to hemostatic RT, bleeding cause (primary tumor
vs. metastasis), WHO bleeding score before hemostatic
RT, use of any other hemostatic measure and dose of
hemostatic RT (< 30 Gy vs. ≥ 30 Gy) were not signifi-
cantly associated with bleeding control at the end of RT.
When the response of bleeding at the end of RT was
analyzed according to the respective bleeding site, it
indicated that lesions in the lung (100% improved), uter-
ovaginal lesions (95% improved) and upper gastrointes-
tinal (GI) lesions (90% improved) showed a better
response than lesions involving the bladder (65%
improved) (Table 4).
Bleeding control at end of follow-up
At the end of follow-up, the incidence of bleeding was
as follows: grade 0 (n= 40), grade 1 (n= 5), grade 2
(n= 1), grade 3 (n= 5) and grade 4 (n= 5). This was sta-
tistically significantly different from the bleeding status
prior to hemostatic RT (p < 0.001, worse = 6, no change =
5, improved = 45) (Figure 1).
The following grades were observed at the end of
follow-up for the 39 patients with no bleeding (grade 0)
at the end of RT: 0 (n= 26), 1 (n= 2), 2 (n= 1), 3 (n= 1)
and 4 (n= 2). At the end of follow-up, the 12 patients
with grade 1 bleeding at the end of RT either had grade
0 (n= 11) or 1 (n= 1) bleeding.
From end of RT to end of follow-up, for those who
could be assessed, the grade worsened in 9 patients,
remained unchanged in 33 and improved in 14
(Figure 2). The change in grade in bleeding scores at
end of follow-up from the end of RT were analyzed
Table 1 Patient Characteristics
Characteristics (N=62) n (%)
Age (years)
Median (range) 66 (37–93)
Sex
Female 32 (52)
Male 30 (48)
Karnowsky PS
Median (range) 40 (20–80)
≤ 40 32 (52)
≥ 50 30 (48)
Site*
Bladder 10 (16)
Lung (NSCLC) 9 (15)
Endometrial 8 (13)
Prostate 6 (10)
Cervical 6 (10)
Gastric 6 (10)
Ovarial 6 (10)
Colorectal 3 (5)
Others# 8 (13)
Histology+
Adenocarcinoma 38 (65)
Squamous cell carcinoma 6 (10)
Transitional cell carcinoma 9 (15)
Others 6 (10)
Tumor-classification+
T0 2 (3)
T3 2 (3)
T4 55 (94)
Metastasis+
No 1 (2)
Yes 52 (88)
Unknown 6 (10)
Liver metastasis+
No 43 (73)
Yes 16 (27)
Bleeding Site+
Primary tumor 48 (81)
Metastasis 11 (19)
Symptom
Vaginal bleeding 19 (31)
Hematuria 17 (27)
Hemoptysis 10 (16)
Others 16 (26)
Table 1 Patient Characteristics (Continued)
First diagnosis to hRT (months)
Median (range) 11 (0.3-183)
Abbreviations: PS=performance status; NSCLC=non-small cell lung cancer;
hRT=hemostatic radiotherapy; *Site of the primary tumor; # including
esophageal (n=2), sarcoma (n=1), multiple myeloma (n=1), kidney cancer
(n=1), non-hodgkin lymphoma (n=1), breast cancer (n=1) and pseudomyxoma
peritonei (n=1); +Three patients were not applicable having stage IV
non-hodgkin lymphoma according to Ann Arbor (n=1) or stage III multiple
myeloma according to Durie and Salmon (n=1) or benign pseudomyxoma
peritonei (n=59).
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ing the bladder (29% worsened) and upper GI (20% wor-
sened) appeared to have worse scores than lung (0%
worsened) or uterovaginal lesions (10.5% worsened)
(Table 4).Table 2 Treatment characteristics
Characteristics (N=62) n (%)
Chemotherapy before hRT
No 29 (47)
Yes 33 (53)
Time last ChT to hRT (months)
Median (range) 3 (0.2-43)
Chemotherapy during hRT
No 60 (97)
Yes 2 (3)
Other RT prior hRT*
No 54 (87)
Yes 8 (13)
Time last RT to hRT (months)
Median (range) 32 (2–128)
Other hemostatic measure
No 49 (79)
Yes 13 (21)
Total hRT dose (Gy)
Median (range) 20 (5–45)
Region treated by hRT
Uterovaginal 19 (31)
Bladder 17 (27)
Lung 10 (16)
Upper GI 10 (16)
Other# 6 (10)
Treatment time hRT (days)
Median (range) 8 (1–25)
Abbreviations: RT=radiotherapy; hRT=hemostatic radiotherapy;
ChT=chemotherapy; GI=gastrointestinal; *in the same region as hemostatic RT;
#including lower gastrointestinal (n=4), skin (n=1) and abdominal wall (n=1).
Table 3 External beam radiotherapy fractionation
schedules and the respective 3-Gy equivalent doses
Fractionation
schedule
Number of patients
in each schedule
(N=47)* n (%)
Total dose
(Gy)
3-Gy ED (Gy)
(α/β=10)
10 x 2 Gy 5 (11%) 20 18.5
15 x 2 Gy 2 (4%) 30 27.7
12 x 2 Gy 1 (2%) 24 22.1
18 x 2.5 Gy 2 (4%) 45 43.3
16 x 2.5 Gy 1 (2%) 40 38.5
10 x 3 Gy 10 (21%) 30 30.0
13 x 3 Gy 2 (4%) 39 39.0
5 x 3 Gy 2 (4%) 15 15.0
9 x 3 Gy 1 (2%) 27 27.0
4 x 3 Gy 1 (2%) 12 12.0
5 x 4 Gy 12 (26%) 20 21.5
4 x 4 Gy 2 (4%) 16 17.2
6 x 4 Gy 1 (2%) 24 25.8
3 x 4 Gy 1 (2%) 12 12.9
5 x 5 Gy 1 (2%) 25 28.8
4 x 5 Gy 1 (2%) 20 23.1
1 x 5 Gy 1 (2%) 5 5.8
1 x 8 Gy 1 (2%) 8 11.1
Abbreviations: ED= equivalent dose; * in 13 patients the single dose was
adapted during RT and 2 patients underwent high-dose rate brachytherapy.
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Four patients (6%) died during RT when the prescribed
dose was not completely delivered for the followingFigure 1 Bar chart showing the proportion of patients with
WHO bleeding grade 0–4 before hemostatic radiotherapy, at
the end of radiotherapy and at the end of follow-up.reasons: bleeding (grade 4) from the irradiated volume
(n=1), kidney failure (n=2) and septicemia (n=1). A fur-
ther 36 patients (58%) died during follow-up; 4 (6%) of
which were attributed to bleeding from the treated site.
Median time to death based on data from all patients
was 2.4 (range, 0.03-30.9) months.
With a median follow-up of 19.3 (range, 0.3-19.3)
months, the 6-month, 1-year and 2-year OS rates were
43%, 24% and 7%, respectively (Figure 3).
In the univariate Cox proportional hazards model, sex
was associated with OS (hazard ratio (HR): 1.967; 95%
Confidence interval (CI): 1.033-3.748; p= 0.0396); male
patients have a greater risk of dying. RT dose was also
associated with OS (HR: 2.669; 95% CI: 1.286-
5.540; p=0.0084); patients who receive a low RT dose
(< 30 Gy) are more likely to die. This was also the case
when the same dose cut-off was used based on the
EQD3 (HR: 2.621; 95% CI: 1.228-5.592; p=0.0127). Fur-
thermore, bleeding grade at the end of RT was associated
with OS (HR: 5.882; 95% CI: 2.445-13.865; p< 0.0001),
patients with bleeding grade≥ 2 are shown to have a
greater risk of dying. In the multivariate analysis higher
bleeding grade at the end of RT and lower RT dose
remained statistically significantly associated with
decreased OS (Table 5).
Acute toxicity
Six patients (10%) experienced grade 1 acute toxicity;
observed symptoms included diarrhea, esophagitis, ab-
dominal pain and vaginitis. Three patients (5%) had
grade 2 acute toxicity with symptoms such as esopha-
gitis, nausea and erythema. No grade 3 or higher acute
toxicities were observed.
Discussion
We are not currently aware of any established standard
therapeutic approach for the treatment of advanced can-
cer patients with clinically significant bleeding as a result
of their cancer. At the moment, treatment decisions are
primarily based on the underlying causes and overall pa-
tient PS. The therapeutic approach varies from comfort
measurement to invasive surgical procedures.
Hemostatic RT is generally believed to be an effective
treatment for patients with bleeding due to cancer. Al-
though bleeding occurs in 6-10% of patients with
advanced cancer [1], relatively little published literature
is available which focuses on bleeding control of
hemostatic RT; even less is known about the optimal RT
total dose and fractionation.
In our retrospective study containing 62 patients with
different primary tumors with significant bleeding (in-
cluding 1 patient whose benign cause of bleeding was
pseudomyxoma pertinonei), it was demonstrated that
hemostatic RT reduced the incidence and grading of
Figure 2 Waterfall plot showing change in bleeding grade at end of RT as compared to baseline (A), change in bleeding grade at end
of follow-up as compared to baseline (B) and change in bleeding grade at end of follow-up as compared to at end of RT (C),
<0 = Improvement; 0 = Stable (no change); >0=Worsened.
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Table 4 Bleeding control by treated site
Treated Site (N) Change in
grade
Baseline to End
of RT n (%)
Baseline to End of
follow-up n (%)
End of RT to End of
follow-up n (%)
Uterovaginal (N=19) Worsened - 1 (5.3%) 2 (10.5%)
No change 1 (5.3%) 1 (5.3%) 10 (52.6%)
Improved 18 (94.7%) 15 (78.9%) 5 (26.3%)
Missing - 2 (10.5%) 2 (10.5%)
Bladder (N=17) Worsened - 2 (11.8%) 5 (29.4%)
No change 6 (35.3%) 4 (23.5%) 8 (47.1%)
Improved 11 (64.7%) 10 (58.8%) 3 (17.6%)
Missing - 1 (5.9%) 1 (5.9%)
Lung (N=10) Worsened - - -
No change - - 6 (60.0%)
Improved 10 (100.0%) 8 (80.0%) 2 (20.0%)
Missing - 2 (20.0%) 2 (20.0%)
Upper GI (N=10) Worsened 1 (10.0%) 3 (30.0%) 2 (20.0%)
No change - - 4 (40.0%)
Improved 9 (90.0%) 6 (60.0%) 3 (30.0%)
Missing - 1 (10.0%) 1 (10.0%)
Other (N=6)* Worsened - - -
No change - - 5 (83.3%)
Improved 6 (100.0%) 6 (100.0%) 1 (16.7%)
Abbreviations: *including lower gastrointestinal (n=4), skin (n=1) and abdominal wall (n=1).
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in the majority of patients. Furthermore, our data sug-
gests an association between a total RT dose > 30 Gy and
increased OS. Male patients and those with a bleeding
grade ≥ 2 at the end of RT were shown to have a greater
risk of dying. Although RT dose remained significantly
associated with OS in the multivariate analysis, we are
aware that this association may be biased due to possibleFigure 3 Kaplan Meier plot of overall survival with 95% confidence inconfounding factors, such as increased dose given to
patients with a higher PS and/or better prognosis.
Bleehen et al. reported almost 20 years ago results
from a phase III trial which compared 2 different frac-
tionation schedules (1 x 10 Gy vs. 2 x 8.5 Gy) as pallia-
tive treatment in 235 patients with incurable locally
advanced NSCLC. One of the symptoms of interest was
hemoptysis which was present in some form in 47% ofterval.
Table 5 Overall survival analysis
Dichotomized variables Associated level OS
Hazard ratio (95% CI) p-value
Univariate analysis
Age > 66 years 0.971 (0.514-1.834) 0.9288
Sex Male 1.967 (1.033-3.748) 0.0396
KPS > 50 0.539 (0.283-1.029) 0.0611
Histology Adenocarcinoma 0.965 (0.510-1.825) 0.9118
Presence of liver metastasis Yes 0.982 (0.463-2.082) 0.9616
Use of chemotherapy before hRT Yes 1.085 (0.572-2.057) 0.8034
Time from first diagnosis to hRT ≥ 12 months 0.804 (0.424-1.524) 0.5037
Other RT prior to hRT Yes 1.411 (0.656-3.034) 0.3785
Use of any other hemostatic measure Yes 1.056 (0.409-2.724) 0.9105
Bleeding cause Primary tumor 1.420 (0.623-3.236) 0.4036
WHO bleeding score before hRT Grade 3 1.380 (0.728-2.617) 0.3239
Dose of hRT < 30 Gy 2.669 (1.286-5.540) 0.0084
WHO bleeding score at end of hRT Grade 2-4 5.882 (2.445-13.865) <0.0001
WHO bleeding score at end of follow-up Grade 2-4 2.006 (0.969-4.154) 0.0609
Multivariate analysis
Sex Male 1.007 (0.487-2.081) 0.9859
Dose of hRT < 30 Gy 2.853 (1.360-5.987) 0.0056
WHO bleeding score at end of hRT Grade 2-4 6.456 (2.645-16.202) <0.0001
Abbreviations: RT=radiotherapy; hRT=hemostatic radiotherapy; KPS=Karnowsky performance score; OS=overall survival.
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72-75% of patients and completely disappeared in 54-
64% of patients. Median duration of this palliative effect
was 64–73 days; no significant difference was observed
between the 2 arms [4]. Similarly, Langendijk et al. pro-
spectively assessed the influence of palliative thoracic RT
using 10 x 3 Gy in 65 patients with incurable NSCLC on
QoL. There was a 79% response rate of hemoptysis after
RT [5]. Comparably, the symptoms of all 10 patients
where lung was the treated site in our retrospective
study improved during RT. There was a 80% CR rate for
bleeding. Furthermore, bleeding remained improved in
80% of patients until the end of follow-up.
Biswal et al. reported a bleeding control of 100% 12-
48 hours after EBRT with 5–20 Gy with/or low-dose
rate brachytherapy with 30 Gy for severe refractory
bleeding caused by cervical cancer. However, in 85%
bleeding was observed again within the following two
years. GI toxicities ≥ grade 2 were observed in 3 patients
[7]. Of the 19 patients who received RT to the uterova-
ginal region in our study, improvement of bleeding dur-
ing RT occurred in 95%, 68% had a CR and bleeding
remained improved until the end of follow-up for 79%.
Srinivasan et al. treated in total 41 cT3-4 patients, with
bladder cancer who had hematuria, with 2 x
8.5 Gy = 17 Gy (EQD3 = 24 Gy) as compared to 12 x
3.75 Gy = 45 Gy. Interestingly, the effect on hematuriawas larger in the 17 Gy hypofractionated patients with
a 59% clearing probability as compared to 16% in the
other group, while toxicity did not differ between the
groups [8]. Others have reported that 6 weeks after pal-
liative RT using 20 Gy in 5 fractions, the bleeding re-
sponse rate was 81% in 31 patients with castrant
resistant prostate cancer, however the response rate
appeared to drop to 42% and 29% after 4 months and
7 months, respectively [9]. Seventeen patients in our
study received RT to the bladder region (for different
primary tumors and histologies, respectively); 65%
showed an improvement in their bleeding during RT,
47% had a CR and 59% remained with improved symp-
toms until the end of follow-up.
Hoskin et al. described the outcome after intraluminal
HDR-B for 50 patients with inoperable cancer of the rec-
tum or anal canal. Treatment was either performed in cura-
tive intent with 6 x 6 Gy = 36 Gy HDR-B monotherapy, 12
Gy HDR-B boost after 45 Gy EBRT (n = 22), or 1 x 10 Gy
HDR-B as palliative treatment (n = 28). Twenty-eight
patients had initial bleeding; a 57% CR rate was obtained in
these patients, with a 10-month median response duration
[10]. In our study only 4 patients with tumors of the lower
GI tract were available, all of whom experienced CR for
bleeding which remained until the end of follow-up.
Hemostatic RT was also used to treat locally advanced
or recurrent gastric cancer. Tey et al.’s study contained
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where 10 x 3 Gy was applied in the majority of cases,
54% showed a reduction in bleeding with median re-
sponse duration of 140 days. No dose–response relation-
ship was observed. One patient experienced grade 3
toxicity [11]. In our study, 10 patients received RT to
the upper GI tract; 5 of whom was to the stomach. A re-
duction in bleeding was observed in 90%, CR in 50% and
durable response in 60%. Notably in 30% of these
patients bleeding worsened during the end of follow-up.
We are aware of the limitations within our retrospect-
ive non-randomized study; no firm conclusions can be
made in regard to the optimal radiation dose. The pos-
sible advantages of using a higher RT dose should be
balanced against potentially higher toxicity in addition
to patient discomfort due to the prolonged treatment
time. Hypofractionation with large single doses may
be useful in case of life-threatening bleeding to in-
duce rapid hemostypsis, but the risks of severe toxi-
cities (Grade 3–5) have to be taken into account
even in this palliative end-of-life setting [13].
We also acknowledge the heterogeneity of our patient
population; several different primary tumors were
involved and ultimately different treatment sites were
targeted by hemostatic RT. While, the total response
rate compares well with the current literature for differ-
ent individual disease types, the bleeding control seemed
to be lower in lesions involving the bladder as compared
to the other treated sites. This finding, however, is again
subject to several potential confounding factors such as
use of different total doses and therefore needs further
confirmation by other studies.
Conclusions
Our data focusing on bleeding control in advanced can-
cer patients strongly suggests that hemostatic RT is a
very effective treatment for significantly reducing bleed-
ing of various primary tumors and treatment sites with-
out major toxicity.
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